Recro Pharma (REPH): Phase 3 Data, A Catalyst This Quarter - HC Wainwright
Tweet Send to a Friend
H.C. Wainwright analyst, Ed Arce, reiterated his Buy rating on shares of Recro Pharma (NASDAQ: REPH) and expects positive Phase ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE